Announced on its homepage: “Brainomix Secures £7m ($9.8m) Investment to Tackle Strokes with AI Brainomix builds on partnership with Boehringer Ingelheim for AI-assis…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
January 2022 – July 2026 · 6 captures · latest observed messagingAI-Enabled Precision
Brainomix has developed automated medical software for stroke image analysis, and lung diseases such as NSCLC and IPF. Our Radiology AI biomarkers enable precision medicine for better treatment.
Seen July 2015 · 1 captureImproving stroke treatment
Brainomix Limited is a start-up company from the University of Oxford. From our roots in the university's software incubator, our aim is to improve the treatment of stroke patients worldwide.